Google.org

GV Investment Managers is a private equity firm founded in 2000 and based in Stamford, Connecticut. The firm specializes in impact investing, private equity, and portfolio management services. It focuses on sectors such as life sciences, consumer products, enterprise solutions, cryptocurrency, climate technology, and frontier innovations. With Alphabet as its sole limited partner, GV Investment Managers primarily targets investments in North America and Europe. The firm collaborates with operating partners who assist startups in areas such as design, diversity and inclusion, talent acquisition, and engineering, while also facilitating connections with Google for technological support and expertise.

Ekta Aggarwal

Principal Account Manager

John Bell

CEO-Founder

Aaron Bell

Director, Google Research

Brendan Bulik-Sullivan

General Partner

Terri Burns

Partner

Brad Calder

VP and GM, Google Cloud Platform and Technical Infrastructure

Sumiran Das

Growth Equity Investor at Google Capital

Jamal Eason

Director of Product Management

Karim Faris

General Partner

Jacquelline Fuller

President

Raj Gajwani

Director, Orion Wifi @ Google Area 120

Margaret Georgiadis

President, Americas

Carletta Higginson

Director, Global Head of Music Publishing

Crystal Huang

Partner

Rahul Jain

Lead, Venture Capital and Startups - Google Cloud

Aftab Jutt

CEO

Sushrut Karanjkar

Director

David Krane

Mnaging Partner

Jess Kuizon

CEO

Skye Lee

Director of UX

Bibiana Leite

Director, Scaled Partnerships

Anthony Nakache

Managing Director, Google MENA

David Reshef

Venture Partner

Issi Rozen

Venture Partner

Philipp Schindler

Senior Vice President and Chief Business Officer

Aparna Sinha

Director, Product Management for Kubernetes and Anthos

Andrew R. Whalley

Director, Chrome Security

Andy Wheeler

General Partner

LightRoom Premium Mod APK Download Android

CEO

Co khi Nhan Do

CEO

Past deals in Health Care

Leyden Labs

Series B in 2025
Leyden Labs is a biotechnology company focused on developing intranasal products aimed at protecting individuals from respiratory viruses. By targeting commonalities among various viral families, Leyden Labs seeks to provide broad-spectrum protection against multiple strains of viruses, including those in the influenza and coronavirus families. Unlike traditional vaccines that typically address specific variants, Leyden Labs' innovative approach allows for simultaneous protection against a range of viruses, thereby empowering individuals to safeguard their health and prevent the transmission of diseases. The company's team comprises experienced biotechnology professionals and new talent, all committed to advancing solutions that alleviate the impact of respiratory infections on global health.

Diverge Health

Series A in 2024
Diverge Health is a healthcare platform designed to support primary care practices in providing quality care to underserved patients. The company enhances these practices by offering a robust infrastructure that includes highly trained community health teams and administrative support. Additionally, Diverge Health integrates technology to facilitate local population health management. This comprehensive approach enables primary care providers to achieve better health outcomes for their patients while successfully navigating the shift towards value-based payment models.

Ubie

Corporate Round in 2024
Ubie, Inc. is a Tokyo-based company founded in 2017 that specializes in developing artificial intelligence-driven healthcare solutions. Its primary product is an AI symptom checker, designed to aid hospitals and physicians by delivering individualized evaluation reports based on patient responses to a brief questionnaire. The system tailors its questions according to various factors, including biological sex, age, medical history, and lifestyle choices. By providing a patient summary and predictive diagnosis, Ubie's technology enhances the diagnostic process, facilitating more personalized care for patients.

Rippl Care

Series A in 2024
Rippl Care is a mental health company based in Seattle, Washington, dedicated to supporting seniors experiencing dementia and other neurocognitive disorders. Founded in 2021, the company employs a value-based approach and innovative technology to deliver comprehensive care tailored to individual needs. By prioritizing the empowerment of its clinicians, Rippl Care adopts a novel care model that enables seniors to receive personalized support through various channels, including phone, online, and in-home visits. This commitment to enhancing the quality of care for those affected by neurocognitive conditions sets Rippl Care apart in the mental health landscape.

AccuLine

Grant in 2024
AccuLine is a digital healthcare company focused on preventing heart attacks by offering innovative solutions for early detection of coronary artery disease (CAD). The company is developing CORA, a non-invasive examination technology that provides a smart, accurate, and user-friendly alternative to traditional stress tests. By streamlining the detection process, CORA enables healthcare providers to identify CAD more swiftly and cost-effectively, ultimately aiming to save millions of lives worldwide through timely intervention.

Midi Health

Series B in 2024
Midi Health is a virtual care clinic dedicated to addressing the health needs of women, particularly during menopause and related conditions. The clinic specializes in treating issues such as depression, gynecological cancer, and menstrual problems through a clinical platform that delivers personalized care protocols. These protocols are administered by clinicians who are trained in female midlife health. Midi Health enhances its services by utilizing specialized at-home labs, providing prescription medications, supplements, and lifestyle coaching. This comprehensive approach aims to empower women to manage the challenges they face during critical stages of their lives and careers.

Benefits Data Trust

Grant in 2024
Founded in 2005, Benefits Data Trust (BDT) is a national not-for-profit organization committed to transforming how individuals in need access essential benefits and services.

Oula Health

Series B in 2024
Oula Health, Inc. specializes in maternity care services, offering both in-clinic and home-based prenatal care. Founded in 2019 and located in Brooklyn, New York, Oula aims to transform the maternity care experience by integrating obstetrics and midwifery. The company focuses on providing a personalized and evidence-based approach to pregnancy, combining modern medical practices with a compassionate understanding of human needs. Through its innovative maternity center, Oula sets a new standard for pregnancy care that emphasizes both medical expertise and personal connection.

Midi Health

Series A in 2023
Midi Health is a virtual care clinic dedicated to addressing the health needs of women, particularly during menopause and related conditions. The clinic specializes in treating issues such as depression, gynecological cancer, and menstrual problems through a clinical platform that delivers personalized care protocols. These protocols are administered by clinicians who are trained in female midlife health. Midi Health enhances its services by utilizing specialized at-home labs, providing prescription medications, supplements, and lifestyle coaching. This comprehensive approach aims to empower women to manage the challenges they face during critical stages of their lives and careers.

MATCH: Music Attuned Technology – Care via eHealth

Grant in 2023
MATCH: Music Attuned Technology – Care via eHealth improves the daily lives of dementia patients, their families, and caregivers by harnessing the power of music.

Caraway

Series A in 2023
Caraway is a digital healthcare company for college women+ that provides integrated mental, reproductive and physical healthcare services. Built with students for students, Caraway arms women+ with the first personalized, equitable and digitally-accessible care solution that prioritizes their needs and concerns. With an unprecedented need for mental health resources and new barriers and persistent inequities in women’s+ health, Caraway provides access to trusted, holistic, and compassionate healthcare so women+ can get the care they need when they need it.

Antiva Biosciences

Series E in 2023
Antiva Biosciences is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral drugs to treat human papillomavirus (HPV) infections. Founded in 2012 and previously known as Hera Therapeutics, the company aims to prevent cancer by addressing precancerous lesions associated with HPV. Antiva's innovative approach involves localized therapeutics and small molecule antivirals designed to improve health outcomes for patients suffering from diseases linked to HPV and other viruses. The company's clinical programs target high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias, utilizing a medicinal chemistry platform that emphasizes the development and commercialization of direct-acting antivirals.

Britto's Brainwaves

Seed Round in 2023
Britto's Brainwaves is a healthcare company that emerges as a beacon for those seeking in-depth medical insights.

Rippl Care

Seed Round in 2022
Rippl Care is a mental health company based in Seattle, Washington, dedicated to supporting seniors experiencing dementia and other neurocognitive disorders. Founded in 2021, the company employs a value-based approach and innovative technology to deliver comprehensive care tailored to individual needs. By prioritizing the empowerment of its clinicians, Rippl Care adopts a novel care model that enables seniors to receive personalized support through various channels, including phone, online, and in-home visits. This commitment to enhancing the quality of care for those affected by neurocognitive conditions sets Rippl Care apart in the mental health landscape.

Sesame

Series B in 2022
Sesame, Inc., also known as SesameCare, is a New York-based company founded in 2018 that specializes in providing a platform for booking medical appointments and consultations. The company distinguishes itself by offering affordable healthcare options, enabling Americans to access quality medical services at significantly reduced prices compared to traditional providers. By utilizing an AI-enabled marketplace, Sesame eliminates the need for insurance, fostering competition among healthcare providers based on quality, accessibility, and pricing. Additionally, Sesame serves as the official telehealth partner of Costco, further enhancing its reach and service offerings in the healthcare sector.

Invetx

Series B in 2022
Invetx, Inc. is a biotechnology company focused on developing protein-based therapeutics for animal health care and veterinary medicine. Based in Boston, Massachusetts, Invetx's team comprises veterinary scientists and clinicians dedicated to discovering and creating biotherapeutics for both pets and farm animals. The company aims to enhance health outcomes in the animal health industry by leveraging biopharma technologies, supported by a network of experts in animal and human health. Through its innovative platform, Invetx is committed to advancing a portfolio of therapies and technologies designed to improve animal care and well-being.

Aspen Neuroscience

Series B in 2022
Aspen Neuroscience, Inc. is a biotechnology company focused on developing induced pluripotent stem cells (iPSCs) to create patient-specific therapies for neurological conditions, particularly Parkinson's disease. Founded in 2018 and based in San Diego, California, the company is advancing its pipeline of products, which includes ANPD001, an autologous neuron replacement therapy for sporadic Parkinson's disease, and ANPD002, a gene-edited autologous neuron replacement therapy targeting familial forms of the disease. Aspen Neuroscience employs innovative genomic approaches in conjunction with stem cell biology to address diseases with significant unmet medical needs, aiming to provide restorative cell therapies that can modify the progression of Parkinson's disease and potentially extend to other affected organs.

Waltz Health

Series A in 2022
Waltz Health is focused on enhancing the pharmaceutical supply chain by collaborating with consumers, payers, and pharmacies to develop innovative, technology-driven solutions for pricing, distribution, and prescription of medications. The company creates AI-driven marketplaces that aim to reduce costs and provide valuable insights for users, facilitating informed decision-making in prescription care. By offering consumer tools designed to empower individuals and help payers manage their pharmacy benefits, Waltz Health strives to improve accessibility and affordability in the healthcare sector.

spunout

Grant in 2022
SpunOut is an Irish non-governmental organization that provides online youth information. It also provides youth information and supportive factsheets on topics such as mental health, politics, physical health, education, and employment.

Leyden Labs

Series B in 2022
Leyden Labs is a biotechnology company focused on developing intranasal products aimed at protecting individuals from respiratory viruses. By targeting commonalities among various viral families, Leyden Labs seeks to provide broad-spectrum protection against multiple strains of viruses, including those in the influenza and coronavirus families. Unlike traditional vaccines that typically address specific variants, Leyden Labs' innovative approach allows for simultaneous protection against a range of viruses, thereby empowering individuals to safeguard their health and prevent the transmission of diseases. The company's team comprises experienced biotechnology professionals and new talent, all committed to advancing solutions that alleviate the impact of respiratory infections on global health.

Quartet Health

Corporate Round in 2021
Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the platform integrates with health plans and systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. By facilitating connections among physicians, mental health providers, and insurers, Quartet Health enhances access to mental health care that aligns with patients' preferences and clinical needs, while also supporting tools for patient self-management. This approach not only improves the quality of care but also contributes to lowering healthcare costs for patients.

Cambridge Epigenetix

Series D in 2021
Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.

Antiva Biosciences

Series D in 2021
Antiva Biosciences is a biopharmaceutical company based in South San Francisco, California, focused on developing antiviral drugs to treat human papillomavirus (HPV) infections. Founded in 2012 and previously known as Hera Therapeutics, the company aims to prevent cancer by addressing precancerous lesions associated with HPV. Antiva's innovative approach involves localized therapeutics and small molecule antivirals designed to improve health outcomes for patients suffering from diseases linked to HPV and other viruses. The company's clinical programs target high-grade anal intraepithelial neoplasias and high-grade cervical intraepithelial neoplasias, utilizing a medicinal chemistry platform that emphasizes the development and commercialization of direct-acting antivirals.

Patina Health

Series A in 2021
Patina is a healthcare provider focused on enhancing the aging experience for older adults and their families. The company has developed a care model that prioritizes the unique needs and values of this demographic. By offering personalized and on-demand services, Patina aims to create a healthcare experience that is both human-centered and supportive. This approach allows families to actively participate in the care of their loved ones, ensuring that older adults receive the attention and respect they deserve as they navigate the challenges of aging. Patina's mission is to empower individuals to live their best lives and maintain their dignity as they age.

Favor

Series B in 2021
Favor is a direct-to-consumer service for women and people who menstruate, that’s on a mission to make healthcare more accessible by building a digital health platform that closes racial, gender and socioeconomic gaps in our healthcare system. Favor is the easiest way for women and people who menstruate to address their sexual health and overall wellbeing, regardless of where they live or if they’re covered by health insurance–making Favor an affordable, accessible telehealth provider.

Leyden Labs

Series A in 2021
Leyden Labs is a biotechnology company focused on developing intranasal products aimed at protecting individuals from respiratory viruses. By targeting commonalities among various viral families, Leyden Labs seeks to provide broad-spectrum protection against multiple strains of viruses, including those in the influenza and coronavirus families. Unlike traditional vaccines that typically address specific variants, Leyden Labs' innovative approach allows for simultaneous protection against a range of viruses, thereby empowering individuals to safeguard their health and prevent the transmission of diseases. The company's team comprises experienced biotechnology professionals and new talent, all committed to advancing solutions that alleviate the impact of respiratory infections on global health.

Tenaya Therapeutics

Series C in 2021
Tenaya Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative therapies for heart disease, particularly heart failure. Established in 2016, the company employs three main platforms to address the underlying causes of heart disease: a cellular regeneration platform that reprograms cardiac fibroblasts into cardiomyocytes using proprietary transcription factors, a gene therapy platform for targeted delivery of therapeutic payloads, and a precision medicine approach tailored to individual patients. Through these platforms, Tenaya Therapeutics aims to enable the regeneration of heart tissue and tackle various forms of cardiomyopathies, leveraging advanced research in cardiac development and regeneration.

Locanabio

Series B in 2020
Locanabio, Inc. is a biotechnology company based in San Diego, California, founded in 2016. It specializes in developing RNA-targeted gene therapies aimed at treating a range of underserved diseases, particularly in the areas of neuromuscular, neurodegenerative, and retinal conditions. The company's innovative platform focuses on modifying disease-causing RNA, allowing for the identification and correction of specific RNA sequences associated with rare genetic disorders. This approach distinguishes Locanabio's therapies from traditional DNA-targeted methods, offering a unique solution for patients with severe and challenging health issues. The company, which rebranded from Locana, Inc. in July 2020, is dedicated to advancing therapeutic candidates that address significant medical needs.

PatientPing

Series C in 2020
PatientPing, Inc. is a health technology company that has established a national care coordination network designed to connect healthcare providers with real-time notifications whenever patients receive care. The network encompasses a diverse group of healthcare personnel, including physicians, nurses, case managers, and care coordinators across various settings such as hospitals, emergency departments, and skilled nursing facilities. PatientPing offers technology solutions tailored to Accountable Care Organizations (ACOs) and other healthcare providers, facilitating improved collaboration and information sharing. One of its key tools, Spotlights, leverages real-time data to identify utilization and performance trends in patient care. Founded in 2013 and headquartered in Boston, Massachusetts, PatientPing operates as a subsidiary of SVB Leerink Holdings LLC and maintains a strategic partnership with MedAllies, Inc. By fostering connections among care teams, PatientPing aims to enhance the quality and efficiency of healthcare delivery, ultimately leading to better patient outcomes.

Aledade

Series C in 2020
Aledade, Inc. is a company that supports primary care physicians in establishing and managing accountable care organizations (ACOs) across the United States. Founded in 2014 and headquartered in Bethesda, Maryland, Aledade provides a comprehensive suite of services including data analytics, guided workflows, regulatory expertise, and payer relationships. The company aims to empower independent primary care providers by offering customized solutions, operational support, and advanced technology to enhance practice efficiency and patient care. Aledade serves a diverse range of healthcare practices, including small and large practices, community health centers, and multispecialty groups. By facilitating better care delivery and reducing overall costs, Aledade helps physicians maintain their independence while improving health outcomes for their patients.

CareBridge Health

Series B in 2019
CareBridge is a technology and services provider based in Nashville, Tennessee, dedicated to improving the lives of individuals with physical, intellectual, or developmental disabilities who receive home and community-based services. Founded in 2009, the company specializes in assisting health plans and states by offering comprehensive solutions such as electronic visit verification, data aggregation, and 24/7 clinical support. CareBridge focuses on ensuring that Medicaid recipients, as well as those dually eligible for Medicare and Medicaid, receive the necessary services, equipment, and support to maintain their independence at home. By facilitating continuous communication between patients, their families, and caregivers, CareBridge enhances the quality of care and promotes a supportive environment for those they serve.

Tenaya Therapeutics

Series B in 2019
Tenaya Therapeutics is a biotechnology company based in South San Francisco, California, focused on developing innovative therapies for heart disease, particularly heart failure. Established in 2016, the company employs three main platforms to address the underlying causes of heart disease: a cellular regeneration platform that reprograms cardiac fibroblasts into cardiomyocytes using proprietary transcription factors, a gene therapy platform for targeted delivery of therapeutic payloads, and a precision medicine approach tailored to individual patients. Through these platforms, Tenaya Therapeutics aims to enable the regeneration of heart tissue and tackle various forms of cardiomyopathies, leveraging advanced research in cardiac development and regeneration.

Quartet Health

Series D in 2019
Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the platform integrates with health plans and systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. By facilitating connections among physicians, mental health providers, and insurers, Quartet Health enhances access to mental health care that aligns with patients' preferences and clinical needs, while also supporting tools for patient self-management. This approach not only improves the quality of care but also contributes to lowering healthcare costs for patients.

Locanabio

Series A in 2019
Locanabio, Inc. is a biotechnology company based in San Diego, California, founded in 2016. It specializes in developing RNA-targeted gene therapies aimed at treating a range of underserved diseases, particularly in the areas of neuromuscular, neurodegenerative, and retinal conditions. The company's innovative platform focuses on modifying disease-causing RNA, allowing for the identification and correction of specific RNA sequences associated with rare genetic disorders. This approach distinguishes Locanabio's therapies from traditional DNA-targeted methods, offering a unique solution for patients with severe and challenging health issues. The company, which rebranded from Locana, Inc. in July 2020, is dedicated to advancing therapeutic candidates that address significant medical needs.

Arrakis Therapeutics

Series B in 2019
Arrakis Therapeutics, Inc. is a biopharmaceutical company focused on developing a proprietary platform for drug discovery that targets ribonucleic acid (RNA). The company aims to identify new RNA targets and create small-molecule drug candidates, primarily addressing cancer and other genetically validated diseases. Its innovative platform combines advanced RNA bioinformatics, structural tools, chemical biology, and medicinal chemistry, facilitating the development of RNA-targeted small molecules (rSMs). Additionally, Arrakis offers SHAPEware, a software tool designed to predict RNA secondary structures and potential ligand-binding sites. Founded in 2015, Arrakis Therapeutics is headquartered in Waltham, Massachusetts, and its work enables improved treatment options for various conditions, including neurological disorders and rare genetic diseases.

Favor

Series B in 2019
Favor is a direct-to-consumer service for women and people who menstruate, that’s on a mission to make healthcare more accessible by building a digital health platform that closes racial, gender and socioeconomic gaps in our healthcare system. Favor is the easiest way for women and people who menstruate to address their sexual health and overall wellbeing, regardless of where they live or if they’re covered by health insurance–making Favor an affordable, accessible telehealth provider.

Cambridge Epigenetix

Series C in 2018
Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.

Barinthus Biotherapeutics

Series A in 2018
Barinthus Biotherapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative immunotherapeutics and vaccines aimed at treating and preventing infectious diseases and cancer. The company utilizes proprietary modified simian adenoviral vectors, specifically ChAdOx1 and ChAdOx2, along with the Modified Vaccinia Ankara (MVA) boost vector, both of which are designed to be safe and non-replicative in humans. This combination approach has demonstrated the ability to generate significantly higher levels of CD8+ T cells compared to other methodologies. Barinthus Biotherapeutics maintains a diverse pipeline that includes both clinical and preclinical therapeutic programs targeting solid tumors, viral infections, and prophylactic viral vaccines. In collaboration with the University of Oxford, the company co-invented a COVID-19 vaccine that has received approval for use in various regions worldwide.

Quartet Health

Series C in 2018
Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the platform integrates with health plans and systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. By facilitating connections among physicians, mental health providers, and insurers, Quartet Health enhances access to mental health care that aligns with patients' preferences and clinical needs, while also supporting tools for patient self-management. This approach not only improves the quality of care but also contributes to lowering healthcare costs for patients.

Senosis Health

Acquisition in 2017
Senosis Health is a mobile health monitoring startup focused on developing applications that facilitate the measurement, diagnosis, and management of various diseases. The company's innovative solutions allow users to monitor critical health metrics, such as lung health and hemoglobin levels, through the capabilities of their smartphones. By utilizing features like the accelerometer, microphone, flash, and camera, Senosis Health provides a user-friendly approach to health management, enabling individuals to take an active role in their healthcare.

Compass Therapeutics

Series A in 2017
Compass Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative antibody therapeutics for the treatment of solid tumors and hematological malignancies. Founded in 2014 and headquartered in Cambridge, Massachusetts, the company utilizes its proprietary StitchMabs and common light-chain platforms to discover and create multispecific antibody combinations. Its lead product candidate, CTX-471, is an agonistic monoclonal antibody targeting CD137, currently undergoing Phase 1 clinical trials in patients with prior PD-1/PD-L1 checkpoint inhibitor treatment. Another significant candidate, CTX-009, is a bispecific antibody that inhibits DLL4-mediated Notch signaling and VEGF-A signaling, having completed a Phase 1 dose escalation study. Additionally, CTX-8371, a bispecific antibody targeting PD-1 and PD-L1, is in the IND-enabling stage. Through its innovative approaches, Compass Therapeutics aims to enhance immune engagement and improve therapeutic outcomes for cancer patients.

CareMessage

Series B in 2017
CareMessage is a technology non-profit dedicated to enhancing patient engagement for low-income populations in the United States. Its platform, powered by the Health Equity Engine™, integrates messaging, data, and interoperability to improve access to care, clinical outcomes, and social determinants of health. Since its inception in 2013, CareMessage has reached 20 million patients, establishing itself as a leader in promoting health equity at scale. The platform offers services that remind and educate patients about primary care appointments, preventive screenings, and disease management, serving community health centers, health plans, and free clinics. With a team that includes individuals with lived experiences in these communities, CareMessage reinvests its revenue into impactful initiatives, positioning itself as a preferred partner for organizations focused on advancing health equity.

Clover Health

Series D in 2017
Clover Health Inc. is a health insurance company that specializes in providing Medicare Advantage plans primarily for senior citizens. Founded in 2014 and headquartered in San Francisco, California, the company operates in several states, including New Jersey, Arizona, Georgia, Pennsylvania, South Carolina, Tennessee, and Texas. Clover Health utilizes a Preferred Provider Organization (PPO) platform to enhance the quality of life for its members and their healthcare providers. The company employs patient-centered analytics and a dedicated care management team to identify potential health risks and deliver preventive care, thereby aiming to minimize avoidable spending and manage chronic diseases. Its proprietary software platform, Clover Assistant, offers personalized insights to physicians, supporting early detection and effective management of chronic conditions. Clover Health generates the majority of its revenue from its insurance segment, which includes both PPO and HMO plans.

Aledade

Series B in 2017
Aledade, Inc. is a company that supports primary care physicians in establishing and managing accountable care organizations (ACOs) across the United States. Founded in 2014 and headquartered in Bethesda, Maryland, Aledade provides a comprehensive suite of services including data analytics, guided workflows, regulatory expertise, and payer relationships. The company aims to empower independent primary care providers by offering customized solutions, operational support, and advanced technology to enhance practice efficiency and patient care. Aledade serves a diverse range of healthcare practices, including small and large practices, community health centers, and multispecialty groups. By facilitating better care delivery and reducing overall costs, Aledade helps physicians maintain their independence while improving health outcomes for their patients.

Quartet Health

Series B in 2016
Quartet Health, Inc. is a healthcare technology company that operates a cloud-based platform designed to enhance communication and collaboration between medical and behavioral health providers. Founded in 2014 and based in New York, the platform integrates with health plans and systems to deliver actionable insights and reports on behavioral health conditions, ultimately aiming to improve patient outcomes. By facilitating connections among physicians, mental health providers, and insurers, Quartet Health enhances access to mental health care that aligns with patients' preferences and clinical needs, while also supporting tools for patient self-management. This approach not only improves the quality of care but also contributes to lowering healthcare costs for patients.

Cambridge Epigenetix

Series B in 2016
Cambridge Epigenetix Limited is a bioscience company based in Babraham, United Kingdom, focused on advancing clinical epigenetics. Founded in 2012, the company specializes in developing innovative tools for epigenetic analysis, particularly through its TrueMethyl technology, which allows for precise sequencing of hydroxymethylcytosine (5hmC) and methylcytosine (5mC). Its product offerings include TrueMethyl 6 and TrueMethyl 24 kits, designed for quantitative measurement and single-base resolution analysis of DNA methylation and hydroxymethylation. Cambridge Epigenetix aims to transform medical diagnostics by simplifying tests for colorectal cancer and other tumors to a single blood draw, leveraging the significant biomarker potential of 5hmC. The company emerged from the University of Cambridge, backed by notable investors including GV, Sequoia, and Syncona. Through its work, Cambridge Epigenetix seeks to enhance diagnostic and prognostic capabilities in medicine, aligning with its mission to improve human health.

PatientPing

Series A in 2015
PatientPing, Inc. is a health technology company that has established a national care coordination network designed to connect healthcare providers with real-time notifications whenever patients receive care. The network encompasses a diverse group of healthcare personnel, including physicians, nurses, case managers, and care coordinators across various settings such as hospitals, emergency departments, and skilled nursing facilities. PatientPing offers technology solutions tailored to Accountable Care Organizations (ACOs) and other healthcare providers, facilitating improved collaboration and information sharing. One of its key tools, Spotlights, leverages real-time data to identify utilization and performance trends in patient care. Founded in 2013 and headquartered in Boston, Massachusetts, PatientPing operates as a subsidiary of SVB Leerink Holdings LLC and maintains a strategic partnership with MedAllies, Inc. By fostering connections among care teams, PatientPing aims to enhance the quality and efficiency of healthcare delivery, ultimately leading to better patient outcomes.

Oscar Health

Venture Round in 2015
Oscar Health is a health insurance company based in New York, founded in 2012 by Joshua Kushner, Kevin Nazemi, and Mario Schlosser. It specializes in offering individual and family health insurance plans, Medicare Advantage programs for seniors, and small group products. Oscar Health aims to enhance the healthcare experience by leveraging technology, design, and data to make services more accessible and user-friendly. The company primarily serves individuals, couples, and families who do not receive employer-sponsored health insurance in select states, including New York, New Jersey, California, and Texas. In addition to traditional insurance offerings, Oscar provides virtual care, doctor support, and appointment scheduling, emphasizing a comprehensive approach to healthcare management.

Spruce Health

Series A in 2015
Spruce Health, Inc. is a healthcare technology company based in San Francisco, California, that offers an interactive mobile application designed to connect patients with dermatologists for the diagnosis and treatment of various skin conditions, including acne, eczema, and psoriasis. Founded in 2013, Spruce Health aims to streamline the healthcare experience by providing a platform that enhances communication between patients and physicians. The company focuses on making healthcare more accessible and affordable, eliminating the common frustrations of long wait times and unexpected costs. By leveraging software to improve the patient-physician relationship, Spruce Health seeks to enhance the quality of care, patient satisfaction, and overall efficiency in healthcare delivery.

CareMessage

Series A in 2015
CareMessage is a technology non-profit dedicated to enhancing patient engagement for low-income populations in the United States. Its platform, powered by the Health Equity Engine™, integrates messaging, data, and interoperability to improve access to care, clinical outcomes, and social determinants of health. Since its inception in 2013, CareMessage has reached 20 million patients, establishing itself as a leader in promoting health equity at scale. The platform offers services that remind and educate patients about primary care appointments, preventive screenings, and disease management, serving community health centers, health plans, and free clinics. With a team that includes individuals with lived experiences in these communities, CareMessage reinvests its revenue into impactful initiatives, positioning itself as a preferred partner for organizations focused on advancing health equity.

SynapDx

Venture Round in 2013
SynapDx is a laboratory testing service provider focused on the early detection of autism spectrum disorders (ASDs) in children. Founded by Stanley Lapidus, the company aims to assist physicians in evaluating developmental disorders through innovative blood-based diagnostic tests and equipment. By collaborating with experts in ASD and gene expression from prominent institutions, SynapDx seeks to enhance the capability of healthcare providers to identify early symptoms of autism. The company is headquartered in Lexington, Massachusetts, and has secured funding from notable investors, including North Bridge Venture Partners, Bain Capital Ventures, and General Catalyst Partners.

Adimab

Series F in 2012
Adimab LLC is a biotechnology company specializing in the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007 and based in Lebanon, New Hampshire, Adimab utilizes a yeast-based platform to create therapeutic antibodies, including IgG and CD3-based bispecific antibodies. The company is recognized for its ability to deliver diverse and high-quality antibody panels that adhere to stringent standards for affinity, epitope coverage, and species cross-reactivity. This capability allows Adimab to support its partners in rapidly expanding their biologics pipelines through various technology access arrangements. The company's work primarily targets the treatment of cancer, autoimmune disorders, and infectious diseases.

Adimab

Series D in 2010
Adimab LLC is a biotechnology company specializing in the discovery, development, and optimization of human monoclonal and bispecific antibodies. Founded in 2007 and based in Lebanon, New Hampshire, Adimab utilizes a yeast-based platform to create therapeutic antibodies, including IgG and CD3-based bispecific antibodies. The company is recognized for its ability to deliver diverse and high-quality antibody panels that adhere to stringent standards for affinity, epitope coverage, and species cross-reactivity. This capability allows Adimab to support its partners in rapidly expanding their biologics pipelines through various technology access arrangements. The company's work primarily targets the treatment of cancer, autoimmune disorders, and infectious diseases.

Navigenics

Venture Round in 2007
Navigenics, Inc. specializes in personalized genetics testing and customized health counseling services aimed at educating individuals and their physicians about genetic predispositions. The company provides genetic information and analysis to help users take informed actions to prevent diseases, achieve earlier diagnoses, and manage health conditions effectively. Navigenics offers its services through a network of medical centers and physicians, as well as through employer wellness programs at major corporations. By empowering individuals with knowledge of their genetic risks, Navigenics aims to enhance overall health outcomes and mitigate the impact of potential health issues.

Warby Parker

Warby Parker is a lifestyle brand that designs and develops prescription glasses, contact lenses, and eyewear accessories, while also offering eye exams and vision tests. The company aims to provide high-quality designer eyewear at accessible prices, addressing the critical issue that approximately one billion people lack access to affordable glasses. By partnering with experienced non-profit organizations, Warby Parker ensures that each sale contributes to giving someone in need access to eyewear, which can significantly impact their quality of life and economic opportunities. The company's revenue primarily comes from the sale of eyewear products and optical services, which are available through its retail stores, website, and mobile applications. Warby Parker's commitment to social responsibility is integral to its business model, as it seeks to combine profitability with positive social impact.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.